Lina M A Abdel Ghany

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Topics

Molecular Docking

Radical Prostatectomy

Epidermal Growth Factor Receptor

Top Venues

Journal of enzyme inhibition and medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Mohamed Elagawany, Lina M A Abdel Ghany, Tarek S Ibrahim, Abdulrhman S Alharbi, Mohamed S Abdel-Aziz, Eman M El-Labbad, Noha Ryad
Development of certain benzylidene coumarin derivatives as anti-prostate cancer agents targeting EGFR and PI3Kβ kinases. Journal of enzyme inhibition and medicinal chemistry 39 (1) (2024)
Heba Abdelmegeed, Lina M A Abdel Ghany, Amira Youssef, Abd-Allah S El-Etrawy, Noha Ryad
Exploring the antitumor potential of novel quinoline derivatives via tubulin polymerization inhibition in breast cancer; design, synthesis and molecular docking. RSC advances 14 (31) (2024)
Heba Abdelmegeed, Lina M A Abdel Ghany, Amira Youssef, Abd-Allah S El-Etrawy, Noha Ryad
Exploring the antitumor potential of novel quinoline derivatives via tubulin polymerization inhibition in breast cancer; design, synthesis and molecular docking. RSC advances 14 (31) (2024)
Mohamed Elagawany, Lina M A Abdel Ghany, Tarek S Ibrahim, Abdulrhman S Alharbi, Mohamed S Abdel-Aziz, Eman M El-Labbad, Noha Ryad
Development of certain benzylidene coumarin derivatives as anti-prostate cancer agents targeting EGFR and PI3Kβ kinases. Journal of enzyme inhibition and medicinal chemistry 39 (1) (2024)
Mohamed Elagawany, Lina M A Abdel Ghany, Tarek S Ibrahim, Abdulrhman S Alharbi, Mohamed S Abdel-Aziz, Eman M El-Labbad, Noha Ryad
Development of certain benzylidene coumarin derivatives as anti-prostate cancer agents targeting EGFR and PI3Kβ kinases. Journal of enzyme inhibition and medicinal chemistry 39 (1) (2024)
Mohamed Elagawany, Lina M A Abdel Ghany, Tarek S Ibrahim, Abdulrhman S Alharbi, Mohamed S Abdel-Aziz, Eman M El-Labbad, Noha Ryad
Development of certain benzylidene coumarin derivatives as anti-prostate cancer agents targeting EGFR and PI3Kβ kinases. Journal of enzyme inhibition and medicinal chemistry 39 (1) (2024)